Allergy Immunotherapy Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Growing Global Burden & Economic Cost of Respiratory and Food Allergies

Direct medical spending and productivity losses from food, nasal, and asthma-linked allergies now exceed USD 110 billion in the United States, amplifying payer appetite for interventions that promise durable relief. Global prevalence continues to climb as urbanization and lifestyle shifts intensify exposure, pushing peanut allergy alone to affect 1.5 million U.S. children. Biologic therapies carry five-figure annual costs, positioning long-course immunotherapy as a comparatively economical option for health systems. Employers recognize that unmanaged allergies drive absenteeism, especially among school-age children whose reactions disrupt parental work schedules. The magnitude of this economic drag supplies momentum for broader reimbursement of disease-modifying therapies.

Expedited Approvals & Reimbursement of SLIT Tablets in US, EU & Japan

Between 2024 and 2025 the FDA, EMA, and PMDA approved multiple pediatric and adult SLIT indications, shrinking regulatory bottlenecks and sharpening the competitive edge of tablet formats. Concurrent payer rule changes added Relative Value Units for home-based dosing and clarified CPT billing, trimming administrative hurdles^{[1]Centers for Medicare & Medicaid Services, “Medicare Physician Fee Schedule and Reimbursement Updates,” CMS, cms.gov}. These synchronized updates lower out-of-pocket costs and accelerate commercial uptake, especially among pediatric cohorts now eligible for earlier treatment. The trajectory signals a virtuous cycle where regulatory validation feeds payer confidence and vice versa.

Inclusion of AIT in Value-Based Care Frameworks

Commercial insurers and Medicare Advantage plans bundled multi-year SLIT and SCIT regimens into performance-tied packages starting in 2024, paying bonuses when symptom control cuts emergency visits and rescue prescriptions. Providers now measure outcomes through remote symptom apps, rendering immunotherapy a quantifiable quality metric. For allergists this model converts previously episodic revenue streams into predictable cash flow, whereas payers benefit from lower total cost of care.

Home-Based Self-Administration Platforms Improving Adherence

Telemedicine startups deliver at-home SLIT kits alongside virtual allergist consultations, removing geographic and scheduling barriers. Platforms such as Wyndly and Curex scaled sharply after introducing subscriptions priced at USD 99 per month and embedding dosing reminders and pollen alerts within mobile apps. Early discontinuation rates drop when patients avoid weekly office visits, confirming convenience as a primary adoption lever. Regulatory acceptance of virtual initiation visits buttresses this shift and widens reach to rural communities.

Low Diagnosis & Therapy Uptake in Low-Income Regions

Many emerging economies lack allergists, diagnostic labs, and reimbursement pathways, forcing patients to rely on over-the-counter drugs that mask rather than resolve disease. Import tariffs and cold-chain challenges inflate extract costs. Public health funding favors infectious disease, delaying large-scale allergy programs. These structural gaps hold back penetration despite rising prevalence and documented productivity losses.

Product-Specific Anaphylaxis Risk & Safety-Monitoring Costs

Registry data recorded 173 immunotherapy-induced anaphylaxis events in Europe during 2024, most within the first treatment week^{[2]European Anaphylaxis Registry, “Allergen Immunotherapy-Induced Anaphylaxis Data 2024,” anaphylaxisregistry.org} . Mandatory post-injection observation and liability premiums weigh on clinic economics, prompting some physicians to drop SCIT services. Needle-free rescue devices such as neffy ease user anxiety but do not eliminate monitoring overhead.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Allergy Immunotherapy Market Segment Analysis

In 2025 Subcutaneous Immunotherapy captured 44.55% Allergy Immunotherapy market share, yet Sublingual Immunotherapy is forecast to outpace with a 15.25% CAGR. The rise stems from home dosing that erases weekly clinic visits, a compelling benefit for working adults and parents. ALK-Abelló’s tablet revenues advanced 24% year over year in 2024, signaling strong uptake. SCIT retains an edge where multiple allergen sensitivities demand custom mixes, but compliance hurdles curb growth. Epicutaneous and oral modalities remain developmental, positioning SLIT as the near-term disruptor of choice.

Digital pharmacies integrate testing, formulation, shipping, and monitoring into single-fee subscriptions that resonate with digitally fluent consumers. Regulatory clearance for virtual initiation visits legitimizes these models. Clinics focused on SCIT grapple with lower revenue per hour and liability risk, pushing some to refer patients to hospital settings. While EPIT and OIT may disrupt long-term, SLIT dominates the growth story through 2031.

Allergic Rhinitis maintained 47.53% of the Allergy Immunotherapy market size in 2025, yet Food Allergy is set to climb at a 16.85% CAGR following PALFORZIA’s toddler label and supportive NIH data showing 100% tolerance in children completing at-home peanut OIT. Biologic approvals targeting food allergy amplify systemic attention and payer openness. Asthma and venom segments remain clinically important niches, while atopic dermatitis emerges as a pipeline frontier.

Peanut, egg, and milk allergies draw investment as early intervention may induce lifelong tolerance. The commercialization of low-cost, non-proprietary OIT regimens threatens branded incumbents, potentially reshaping competitive dynamics. Meanwhile rhinitis growth decelerates as biologics compete for moderate-to-severe cases.

Injectable Suspensions held 45.63% revenue share in 2025, yet Sublingual Tablets will advance at a 15.87% CAGR as standardized dosing, shelf stability, and pediatric approvals widen adoption. Tablets reduce cold-chain and contamination concerns inherent to multi-dose droppers. Regulatory agencies prioritize tablet reviews, cementing their standing as the default SLIT vehicle.

Drops retain utility where compounded mixtures address polysensitized patients, but adherence declines when patients must count drops daily. Transdermal patches offer potential once adhesion and efficacy hurdles are cleared. For now tablet convenience, precision, and reimbursement alignment underpin their steep growth curve.

Retail and Hospital Pharmacies controlled 51.23% of 2025 revenue; however, e-commerce and mail-order outlets will log a 17.7% CAGR through 2031 as telemedicine platforms bundle formulation, virtual oversight, and doorstep delivery. These models slash middle-mile costs while embedding digital reminders that uplift adherence. Physician-dispensed SCIT extracts persist, but shrinking clinic capacity and rising liability premiums propel a shift toward tablet-centric mail fulfillment.

Regulatory green lights for tele-initiation visits fuel adoption in rural settings. Pharmacy chains adapt by adding online portals, yet pure-play digital platforms retain a user-experience edge. Overall channel dynamics mirror broader healthcare’s tilt toward home-based care.

Geography Analysis

North America Allergy Immunotherapy Market

North America contributed 42.53% of 2025 revenue, buoyed by Medicare reimbursement updates and dense allergist networks. FDA pediatric label expansions unlocked new cohorts and consolidated the United States as the single largest Allergy Immunotherapy market. Canadian approvals pending as of 2025 and Mexican private-insurance uptake maintain regional momentum, though biologic competition tempers long-term growth.

APAC Allergy Immunotherapy Market

Asia-Pacific is projected to record a 15.21% CAGR, the fastest among regions. Japan’s 2024 approval of ITULAZAX for cedar pollen meets a widespread seasonal burden, with Torii Pharmaceutical data showing year-over-year efficacy gains. Chinese authorities require bridging trials for tablets, pushing initial focus to SCIT, while India’s 2025 launch of a house dust mite tablet leverages local distribution heft. Rising disposable income and urban allergy prevalence drive demand across South Korea and Australia.

EMEA and South America Allergy Immunotherapy Market

Europe remains a mature but vital market, accounting for 71% of ALK-Abelló revenue in 2024. Germany tops country sales, supported by Therapieallergene-Verordnung provisions that sustain named-patient supply during regulatory review^{[3]Allergy Therapeutics plc, “Transforming Lives: Annual Report and Accounts 2023,” Allergy Therapeutics, allergytherapeutics.com}. EMA approval of neffy in 2024 adds anaphylaxis management to the regional portfolio. Pricing pressures and generic entrants limit pricing power, yet broad reimbursement keeps volumes stable. Middle East and Africa and South America trail due to sparse allergist networks and limited public funding. Pilot projects hint at future upside but near-term contributions remain modest.

Regulatory Landscape

Regulatory oversight for allergy immunotherapy is anchored in biologics and allergen product pathways, with pediatric label expansions acting as a key mechanism for market widening. In the United States, the FDA approved ALK-Abello's ODACTRA for children aged 5-11 years in February 2025 and expanded PALFORZIA (Stallergenes Greer) to toddlers aged 1-3 years in July 2024, reinforcing earlier-intervention paradigms for both respiratory and food allergy immunotherapy. In February 2024, the FDA also approved Xolair (omalizumab) to reduce allergic reactions to multiple foods after accidental exposure, shaping the broader therapeutic context in which immunotherapy regimens are reimbursed and prescribed.

A persistent regulatory split influences product strategy and channel behavior. FDA-cleared SLIT tablets follow formal labeling and pharmacovigilance requirements, while compounded SLIT liquid drops are not FDA-approved products and operate under a different compliance posture that constrains promotional claims and standardization. In Europe, EMA guidance and scientific advice processes are used to navigate development challenges such as moderate to low-sized study populations, while country-specific frameworks, notably Germany's Therapieallergene-Verordnung environment, continue to push manufacturers toward fully licensed allergen products and away from legacy, less-standardized supply models.

Market Opportunities and Future Outlook

China stands out as a whitespace for branded SLIT tablets, since national regulatory gates and local pivotal-trial requirements influence entry timing and partnership choices. In May 2026, Nuance Pharma reported NMPA IND clearance to run a pivotal clinical trial of Actair for house dust mite-induced allergic rhinitis in China, providing a defined route for multinational tablet franchises to convert demand into reimbursable prescriptions through locally accepted evidence packages. This connects with the report's channel shift toward home-based dosing and mail-order fulfillment, since tablet formats align more readily with standardized distribution and monitoring models than clinic-mixed extracts.

Product innovation is also creating room for differentiated, shorter-course and non-invasive modalities aimed at easing adherence and safety-monitoring friction seen with injectable regimens. In June 2026, DBV Technologies communicated its plan to submit a BLA for the VIASKIN Peanut Patch in children aged 4-7 years (targeting Q3 2026), and Immunomic Therapeutics reported first patient dosed in July 2026 for ITI-9001, reflecting continued investment in next-generation platforms beyond conventional SCIT and tablet SLIT. Capacity and supply resilience is becoming another commercial lever for established manufacturers, as investments that expand industrial output and secure allergen source materials can support tender participation, payer contracting, and broader geographic coverage when demand rises in high-burden indications such as house dust mite allergy.